Prolacta Lands Series D

Monrovia, California-based Prolatca Bioscience, which supplies human milk-based fortifiers for premature infants, said today that it has closed a Series D funding round. The round came from Health Evolution Partners. Size of the round was not announced by the company, however, a regulatory filing by the firm yesterday indicates the equity funding was worth $15.0M. As part of the funding, Joshua Saipe and Ned Brown, both of Health Evolution Partners, have joined the company's board of directors. Prolacta uses human breast milk to develop fortifiers used to feed and treat premature infants; the firm's products avoid a potential, dangerous complication (necrotizing enterocolitis) that can occur when cow-based fortifiers are fed to premature infants. More information »